Ocular Therapeutix Inc Dossier
Qualitative Analysis
Business overview
Ocular Therapeutix, Inc. is a clinical-stage biopharmaceutical company pioneering the development and commercialization of innovative therapies for diseases and conditions of the eye. The company leverages its proprietary ELUTYX™ bioresorbable hydrogel technology platform to formulate sustained-release therapeutics, aiming to replace traditional, high-frequency topical eye drops and monthly intravitreal injections. Its primary commercial product is DEXTENZAu0000, an FDA-approved dexamethasone ophthalmic insert for treating post-surgical ocular inflammation and pain. The company's high-potential pipeline is led by AXPAXLI™ (axitinib intravitreal hydrogel implant), currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel implant, and preparing for an FDA NDA submission in wet AMD.
Expected impact: Potential regulatory approval and commercial launch of a highly differentiated, long-acting treatment for wet AMD.
Conducting the HELIOS-3 Phase 3 clinical trial evaluating AXPAXLI in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Expected impact: Expands the target addressable market for AXPAXLI into diabetic retinal diseases.
Expanding internal manufacturing capabilities, completing scale-up validation runs, and preparing commercial infrastructure for the potential launch of AXPAXLI.
Expected impact: Ensures robust supply chain readiness and commercial execution capability upon regulatory approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on the development and commercialization of DEXTENZA and product candidate OTX-TIC in mainland China, Taiwan, Hong Kong, Macau, South Korea, and ASEAN countries.
Terms: Development and commercialization rights granted for specific Asian territories under defined milestone and royalty terms.